Indian Patent Office Speeds Up Examination Process; Clears Roche’s Pegasys, Rejects Pfizer’s Caduet and Gilead’s Tamiflu
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Over the last two months, the Indian Patent Office has gone ballistic in clearing patent applications filed by multinational companies for several of their key drugs